HRP20070421T3 - Ariloksialkilkarbamatni derivati, njihova priprema i terapeutska primjena - Google Patents

Ariloksialkilkarbamatni derivati, njihova priprema i terapeutska primjena

Info

Publication number
HRP20070421T3
HRP20070421T3 HR20070421T HRP20070421T HRP20070421T3 HR P20070421 T3 HRP20070421 T3 HR P20070421T3 HR 20070421 T HR20070421 T HR 20070421T HR P20070421 T HRP20070421 T HR P20070421T HR P20070421 T3 HRP20070421 T3 HR P20070421T3
Authority
HR
Croatia
Prior art keywords
group
cycloalkyl
phenyl
alkyl
alkylene
Prior art date
Application number
HR20070421T
Other languages
English (en)
Inventor
Abouabdellah Ahmed
Almario Garcia Antonio
Froissant Jacques
Hoornaert Christian
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of HRP20070421T3 publication Critical patent/HRP20070421T3/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Spoj formule (I) naznačen time da: m predstavlja 0, 1, 2 ili 3; n predstavlja 0, 1, 2 ili 3; X predstavlja atom kisika ili sumpora ili grupu SO ili SO2;R1 i R2 predstavljaju, neovisno jedan od drugog, atom vodika ili C1-3-alkilnu grupu, ili R1 i R2 zajedno tvore -(CH2)p- grupu, gdje p predstavlja cijeli broj između 1 i 5, tako da n + p iznosi cijeli broj od 2 do 5; R3 predstavlja atom vodika ili fluora ili hidroksi- ili metilnu grupu; R4 predstavlja grupu opće formule CHR5CONHR6 u kojojR5 predstavlja atom vodika ili C1-6-alkilnu grupu, a R6 predstavlja atom vodika ili C1-6-alkilnu, C3-7-cikloalkilnu, C3-7-cikloalkil-C1-6-alkilensku grupu; Y predstavljaY1 grupu, izabranu naročito između fenila, piridinila, piridazinila, pirimidinila, pirazinila, triazinila, tiazolila, naftila, kinolinila, izokinolinila, ftalazinila, kinazolinila, kinoksalinila, naftiridinila, kinolinila, benzofuranila, dihidrobenzofuranila, benzotienila, dihidrobenzotienila, indolila, izoindolila, indolinila, benzimidazoilila, benzoksazolila, benzizoksazolila, benzotiazolila, benzizotiazolila, benzotriazolila, benzoksadiazolila, benzotiadiazolila; pri čemu je Y1 grupa eventualno supstituirana jednim ili više Y2 supstituenata, identičnih ili različitih jedan od drugog, ili grupom Y3; Y2 predstavlja halogeni atom, grupu cijano, nitro, C1-8-alkil, C1-8-alkoksi, C1-8-tioalkil, C1-8-fluoroalkil, C1-8-fluoroalkoksi, C1-8-fluorotioalkil, C3-7-cikloalkil, C3-7-cikloalkiloksi, C3-7-cikloalkil-C1-8-alkilen; C3-7-cikloalkil-C1-8-alkiloksi, hidroksi, NR7R8, NHCOR7, NHSO2R7, COR7, CO2R7, CONR7R8, SO2R7, SO2NR7R8, -O-(C1-3-alkilen)-O-, feniloksi, feniltio, fenil-C1-C8-alkilen, fenil-C1-C8-alkiloksi ili fenil-C1-C8-alkiltio; Y3 predstavlja grupu izabranu naročito između fenila, piridinila, pirimidinila, pirazinila ilipiridazinila; grupa (grupe) Y3 može biti supstituirana jednom ili više Y2 grupa, identičnih ili međusobno različitih; R7 i R8 predstavljaju, neovisnojedan od drugog, atom vodika ili C1-6-alkilnu grupu, ili, zajedno s atomom dušika na koji su vezani, tvore azetidinski, pirolidinski, piperidinski, morfolinski, tiomorfolinski, azepinski ili piperazinski prsten, po želji supstituiran C1-3-alkilnom ili benzilnom grupom; u obliku baze, kisele adicijske soli, hidrata ili solvata. Patent sadrži još 12patentnih zahtjeva.
HR20070421T 2004-01-16 2007-09-13 Ariloksialkilkarbamatni derivati, njihova priprema i terapeutska primjena HRP20070421T3 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0400389A FR2865205B1 (fr) 2004-01-16 2004-01-16 Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
PCT/FR2005/000028 WO2005077898A1 (fr) 2004-01-16 2005-01-07 Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
HRP20070421T3 true HRP20070421T3 (hr) 2007-10-31

Family

ID=34707893

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20070421T HRP20070421T3 (hr) 2004-01-16 2007-09-13 Ariloksialkilkarbamatni derivati, njihova priprema i terapeutska primjena

Country Status (29)

Country Link
US (3) US7439257B2 (hr)
EP (1) EP1708994B1 (hr)
JP (1) JP4705590B2 (hr)
KR (1) KR101171462B1 (hr)
CN (1) CN100537534C (hr)
AR (1) AR047384A1 (hr)
AT (1) ATE369336T1 (hr)
AU (1) AU2005212868B2 (hr)
BR (1) BRPI0506918A (hr)
CA (1) CA2552565C (hr)
CY (1) CY1106918T1 (hr)
DE (1) DE602005001930T2 (hr)
DK (1) DK1708994T3 (hr)
ES (1) ES2289701T3 (hr)
FR (1) FR2865205B1 (hr)
HK (1) HK1101283A1 (hr)
HR (1) HRP20070421T3 (hr)
IL (1) IL176769A (hr)
MA (1) MA28343A1 (hr)
ME (1) MEP26408A (hr)
NO (1) NO20063681L (hr)
NZ (1) NZ548530A (hr)
PL (1) PL1708994T3 (hr)
PT (1) PT1708994E (hr)
RS (1) RS50518B (hr)
RU (1) RU2392269C2 (hr)
TW (1) TWI402067B (hr)
WO (1) WO2005077898A1 (hr)
ZA (1) ZA200605698B (hr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866884B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique
FR2866888B1 (fr) * 2004-02-26 2006-05-05 Sanofi Synthelabo Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
US7269708B2 (en) * 2004-04-20 2007-09-11 Rambus Inc. Memory controller for non-homogenous memory system
CA2598294C (en) 2005-02-17 2011-10-18 Astellas Pharma Inc. Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative
US7918848B2 (en) 2005-03-25 2011-04-05 Maquet Cardiovascular, Llc Tissue welding and cutting apparatus and method
US8197472B2 (en) 2005-03-25 2012-06-12 Maquet Cardiovascular, Llc Tissue welding and cutting apparatus and method
PE20070099A1 (es) 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
WO2008023720A1 (fr) * 2006-08-23 2008-02-28 Astellas Pharma Inc. COMPOSÉ D'URÉE OU SEL DUDIT COMPOSé
KR101443573B1 (ko) 2006-10-12 2014-11-03 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
UA97817C2 (ru) * 2006-12-06 2012-03-26 Глаксосмиткляйн Ллк Гетероциклические производные 4-(метилсульфонил)фенила и их применение
PE20090595A1 (es) * 2007-08-15 2009-06-06 Glaxo Group Ltd Derivados de quinoliniloxipiperidina y pirrolidina como antagonistas del receptor h1
EP2205585A1 (en) * 2007-10-16 2010-07-14 Glaxo Group Limited Quinoline derivatives used to treat inflammatory and allergic diseases
US9402680B2 (en) 2008-05-27 2016-08-02 Maquet Cardiovasular, Llc Surgical instrument and method
US9968396B2 (en) 2008-05-27 2018-05-15 Maquet Cardiovascular Llc Surgical instrument and method
EP3175806B1 (en) 2008-05-27 2018-10-17 Maquet Cardiovascular LLC Surgical instrument
TW201044234A (en) * 2009-06-08 2010-12-16 Chunghwa Picture Tubes Ltd Method of scanning touch panel
US9955858B2 (en) * 2009-08-21 2018-05-01 Maquet Cardiovascular Llc Surgical instrument and method for use
CA2787476C (en) * 2010-01-20 2017-07-11 Sanofi Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001523695A (ja) * 1997-11-24 2001-11-27 ザ スクリップス リサーチ インスティテュート ギャップ結合連絡の阻害剤
KR20010087125A (ko) 1998-04-16 2001-09-15 데이비드 비. 맥윌리암스 인테그린 수용체에 대한 인테그린의 결합을 억제하는 화합물
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
IL158300A0 (en) * 2001-04-27 2004-05-12 Bristol Myers Squibb Co Bisarylimidazol derivatives and pharmaceutical compositions containing the same
US6949574B2 (en) * 2002-02-08 2005-09-27 Bristol-Myers Squibb Company (Oxime)carbamoyl fatty acid amide hydrolase inhibitors
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
US7176201B2 (en) * 2002-10-07 2007-02-13 The Regents Of The University Of California Modulation of anxiety through blockade of anandamide hydrolysis
BR0314980A (pt) * 2002-10-08 2005-08-09 Scripps Research Inst Inibidores de hidrolase de amida de ácido graxo
FR2850377B1 (fr) * 2003-01-23 2009-02-20 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
CN100537534C (zh) 2009-09-09
DE602005001930T2 (de) 2008-04-30
TWI402067B (zh) 2013-07-21
AU2005212868B2 (en) 2011-04-21
HK1101283A1 (en) 2007-10-12
CA2552565A1 (fr) 2005-08-25
RU2006129640A (ru) 2008-02-27
ZA200605698B (en) 2007-11-28
EP1708994B1 (fr) 2007-08-08
FR2865205A1 (fr) 2005-07-22
ATE369336T1 (de) 2007-08-15
AR047384A1 (es) 2006-01-18
IL176769A0 (en) 2006-10-31
CN1922138A (zh) 2007-02-28
RS50518B (sr) 2010-05-07
AU2005212868A1 (en) 2005-08-25
KR20070000478A (ko) 2007-01-02
US8026258B2 (en) 2011-09-27
JP2007522111A (ja) 2007-08-09
JP4705590B2 (ja) 2011-06-22
CA2552565C (fr) 2013-12-31
MEP26408A (en) 2010-06-10
PL1708994T3 (pl) 2008-01-31
PT1708994E (pt) 2007-10-02
US7674805B2 (en) 2010-03-09
MA28343A1 (fr) 2006-12-01
NO20063681L (no) 2006-09-18
DE602005001930D1 (de) 2007-09-20
EP1708994A1 (fr) 2006-10-11
US20080312262A1 (en) 2008-12-18
NZ548530A (en) 2010-02-26
FR2865205B1 (fr) 2006-02-24
US7439257B2 (en) 2008-10-21
WO2005077898A1 (fr) 2005-08-25
US20100120845A1 (en) 2010-05-13
US20070021424A1 (en) 2007-01-25
BRPI0506918A (pt) 2007-06-05
KR101171462B1 (ko) 2012-08-07
TW200536524A (en) 2005-11-16
IL176769A (en) 2010-06-30
RU2392269C2 (ru) 2010-06-20
DK1708994T3 (da) 2007-11-26
ES2289701T3 (es) 2008-02-01
CY1106918T1 (el) 2012-09-26

Similar Documents

Publication Publication Date Title
HRP20070421T3 (hr) Ariloksialkilkarbamatni derivati, njihova priprema i terapeutska primjena
RS50542B (sr) Derivati alkilpiperazin- i alkilhomopiperazin-karboksilata, postupci za njihovo dobijanje i njihova primena kao inhibitora enzima faah
RS50606B (sr) Supstituisani morfolin i tiomorfolin derivati
RS53682B1 (en) PIRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASE
RS52702B (en) CARBASOL UNITS AND THERAPEUTIC USE OF THE COMPOUNDS
CO4950619A1 (es) Derivados de acido arilsulfonil hidroxamico
ATE191481T1 (de) Indolderivate als 5-ht1-like agonisten
NO20091562L (no) 2-aryl-6-fenylimidazol{1,2-alpha}pyridin derivater, femstilling derav samt terapeutisk anvendelse derav
HRP20090294T1 (hr) Derivati piperidinilalkilkarbamata, postupak njihovog dobivanja i njihova upotreba kao inhibitora enzima faah
HRP20000854B1 (en) Therapeutic biaryl derivatives
HUP0400989A2 (hu) Helyettesített 2-piridin-ciklohexán-1,4-diamin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EE05083B1 (et) Dopamiini neurotransmissiooni modulaatorid, nendekasutamine ja neid hendeid sisaldavad farmatseutilised kompositsioonid
AR086144A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
WO2008155668A3 (en) Heteroarylamide pyrimidone compounds
RS50853B (sr) Derivati n-(1h-indolil)-1h-indol-2-karboksamida, njihova priprema i njihova primena u terapiji
EA200971060A1 (ru) Гетероариламидные пиримидоновые производные
TW200505899A (en) 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
HRP20090050T3 (hr) Novi derivati pirolifin-3, 4-dikarboksamida
DK0790248T3 (da) 3-Aza-piperidon-(tetrahydropyrimidin-2-on)- og 3-oxa-piperidon-(1,3-oxazin-2-on)-derivater, deres fremstilling og deres anvendelse som tachykinin/neurokinin-antagonister
NO812355L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,1-benzoksazin-2-on-derivater
RS51246B (sr) Derivati heteroarila-alkilkarbamata, njihovo dobijanje i njihova primena kao inhibitora faah enzima
IS6452A (is) Ný tetrahýdrópýridín, framleiðsluaðferð og lyfjasamsetningar sem innihalda þau
RS50289B (sr) Novi razgranati supstituisani amino derivati od 3-amino-1- fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
MY138865A (en) New tricyclic azepine compounds, a process for their preparation and pharmaceutical compositions containing them
RS52368B (en) S1P1 BINDING INHIBITORS